Abstract
1. Since the activity of monoclonal antibodies (MAbs) is, in general, limited to the epitopes which they bind, it is often possible to anticipate (and sometimes predict) the effects which such molecules will have in treated animals. By taking a mechanistic approach, a rational and tailored programme of non-clinical safety assessment of MAbs can be adopted.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Bugelski, P. (1998). Designing non-clinical safety evaluation programmes for monoclonal antibodies for therapeutic use: A personal view. In: Griffiths, S.A., Lumley, C.E. (eds) Safety Evaluation of Biotechnologically-derived Pharmaceuticals. CMR International Workshop Series. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-4876-4_9
Download citation
DOI: https://doi.org/10.1007/978-94-011-4876-4_9
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-6043-1
Online ISBN: 978-94-011-4876-4
eBook Packages: Springer Book Archive